Pharma companies can address the opioid crisis by changing their approach to marketing
As pressure to address the opioid crisis mounts, pharma companies are evaluating their marketing strategies and tactics.
Commercial
Half year pro ad report 2018: Journal ad pages jump 1.4%
Spending in medical journals during the first half of 2018 may not have reached the levels seen in the recent past. At the same time, pharma companies don’t appear to be trimming their investments.
FDA turns attention to vapes in latest version of Real Cost anti-tobacco campaign
An estimated 10.7 million teens are vaping or thinking about it.
With a nod from the FDA, Teva enters white-hot migraine market
Teva’s Ajovy becomes the second approved CGRP migraine therapy, following Amgen’s Aimovig.
7 must-haves for effective market access programs
How does one create an effective market access program in the current healthcare environment? Experts share seven tips for success.
After failure of generic fish oil trial, some caution against read-across to Vascepa study
Amarin’s Vascepa trial is set to read out results by the end of September.
Got name? A peek into the sometimes bizarre land of pharma brand-naming
As more medications are approved, pharma companies are being pushed farther afield into a land of bizarre — but hopefully still memorable and vaguely meaningful — drug names.
Behind the Exact Sciences/Pfizer Cologuard co-promotion deal
The companies plan to make the most of favorable market access conditions for the at-home colon cancer screening test.
Pfizer lawsuit could clear path for biosimilars
Biosimilars have only been in the market for three years, but they have struggled to compete with their branded equivalents.
Novo Nordisk’s Ozempic takes on Lilly’s Trulicity in DTC showdown
The two diabetes rivals air competing TV spots as they compete for GLP-1 supremacy.
Want to read more?
Please login or register first to view this content.
